Graves' disease is an autoimmune disorder that results into overproduction of thyroid hormones.
Thyrotoxicosis signs and symptoms include hyperactivity, irritability, insomnia, dysphoria, sweating, heat intolerance, palpitations, weakness, fatigue, weight loss despite increased appetite, diarrhea, steatorrhea polyuria, decreased libido, tachycardia, tremor, goiter, alopecia, gynecomastia, eyelid lag or retraction and rarely periodic paralysis.
Clinical features in thyrotoxic patient that suggests Graves's disease are ophthalmopathy, thyroid dermopathy, thyroid acropachy, diffuse goiter, antibodies to thyroid peroxidase or thyroglobulin and thyroid radionuclide scan demonstrating a diffuse goiter.


  • Graves’ disease is an autoimmune disorder in which thyrotropin receptor antibodies stimulate the thyroid stimulating hormone (TSH) receptor, increasing thyroid hormone production
    • Most common cause of hyperthyroidism

Signs and Symptoms

Signs & Symptoms of Thyrotoxicosis
  • Hyperactivity, irritability, insomnia, dysphoria
  • Sweating, heat intolerance
  • Palpitations
  • Weakness, fatigue
  • Wt loss w/ increased appetite
    • Wt gain may occur
  • Diarrhea, steatorrhea, polyuria
  • Decreased libido, oligomenorrhea
  • Tachycardia, atrial fibrillation in the elderly
  • Tremor
  • Goiter
  • Alopecia, gynecomastia
  • Eyelid lag or retraction
  • Rarely periodic paralysis (more often in Asian men)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Editor's Recommendations
Most Read Articles
13 Mar 2018
In obese patients with type 2 diabetes mellitus (T2DM), higher plasma levels of leptin appear to be associated with better sleep quality, a recent study has shown.
Roshini Claire Anthony, 4 days ago

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

22 Jun 2017
Circulating glucagon-like peptide 1 (GLP-1) levels increase with chronic and acute inflammatory processes like sepsis and chronic kidney disease, a recent study has found.
01 Jun 2015
New drug applications approved by US FDA as of 15 – 31 May 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.